TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Last trade$0.1438
Day change-$0.0013 (-0.90%)
Day range$0.14 – $0.166
Volume181,162
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.17M
Price / earnings
—
Price / book
0.27×
Price / sales
1.96×
EV / sales
-5.77×
EV / EBITDA
0.26×
Profitability
Earnings per share
-$1.70
Return on assets
-81.39%
Return on equity
-302.77%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.87×
Current ratio
2.03×
Quick ratio
2.03×
Cash ratio
1.93×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$111.27M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TCRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$586K
$1.05M
$982K
$2.57M
$2.51M
$3.08M
$2.17M
$665K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$586K
$1.05M
$982K
$2.57M
$2.51M
$3.08M
$2.17M
$665K
Selling, general and administrative
$8.33M
$8.14M
$8.22M
$6.39M
$7.87M
$9.1M
$8.63M
$8.02M
Research and development
$25.29M
$23.4M
$21.9M
$20.04M
$31.69M
$32.63M
$29.79M
$29.35M
Total operating expenses
$33.62M
$31.54M
$30.12M
$26.43M
$39.56M
$41.73M
$38.42M
$37.38M
Operating income
-$33.03M
-$30.49M
-$29.14M
-$23.86M
-$37.05M
-$38.65M
-$36.25M
-$36.71M
Interest expense
-$775K
-$699K
-$689K
-$702K
-$699K
-$689K
-$679K
-$784K
Income before taxes
-$33.09M
-$30.36M
-$28.67M
-$22.98M
-$35.71M
-$36.95M
-$34.13M
-$35.81M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$33.09M
-$30.36M
-$28.67M
-$22.98M
-$35.71M
-$36.95M
-$34.13M
-$35.81M
Net income attributable to common shareholders
-$33.09M
-$30.36M
-$28.67M
-$22.98M
-$35.71M
-$36.95M
-$34.13M
-$35.81M
EBITDA
-$32.35M
-$29.79M
-$28.45M
-$23.14M
-$36.29M
-$37.96M
-$35.57M
-$36M
Basic earnings per share
-$0.25
-$0.23
-$0.22
-$0.18
-$0.28
-$0.28
-$0.26
-$0.30
Diluted earnings per share
-$0.25
-$0.23
-$0.22
-$0.18
-$0.28
-$0.28
-$0.26
-$0.30
Recent news
Company coverage with links to the original publishers.
TScan Therapeutics reported positive results from Cohort C of its Phase 1 ALLOHA study of TSC-101, a TCR-engineered T cell therapy for hematologic malignancies. 11 of 14 patients achieved complete donor chimerism within three weeks of the first infusion, with all 5 patients assessed after a second infusion showing complete chimerism. The commercial-ready manufacturing process achieved a 90% success rate. The company remains on track to initiate its Phase 3 ALLOHA-2 study this month.
TScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of TSC-101 in Q2 2026, and Phase 1 studies of TSC-102-A01 and TSC-102-A03 in H2 2026. Cash position of $128.1 million is expected to fund operations into H2 2027.
TScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for candidates TSC-102-A01 and TSC-102-A03.
TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA types A*01:01 and A*03:01. The company plans to share safety and chimerism data in Q2 2026 and launch a pivotal trial for TSC-101, while initiating Phase 1 studies for both TSC-102 candidates in the second half of 2026.
TScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.